Takeda receives positive chmp opinion for fruquintinib in previously treated metastatic colorectal cancer

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (vegfr) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mcrc). the european commission (ec) will consider the chmp positive opinion when.
TAK Ratings Summary
TAK Quant Ranking